Notícias e Atividades da Fractyl Laboratories

Veja o organograma con seus 22 executivos principais

Biografias mais buscadas da Fractyl Laboratories

• Harith Rajagopalan, Chief Executive Officer and Director
• Kelly Barnes, Director
• Marc Elia, Director

Recentes movimentos de executivos em Fractyl Laboratories

• Lara Smith Weber, ingressou na Companhia como Chief Financial Officer  (Notícia publicada em 27 de fevereiro de 2026).
• Lisa Davidson, Chief Financial Officer, deixou a Companhia  (Notícia publicada em 27 de fevereiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Fractyl Laboratories.

Fractyl Laboratories possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Fractyl Laboratories

• Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 | Fractyl Health, Inc.
• Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort | Fractyl Health, Inc.
• Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Fractyl Health, Inc.
• Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Frac
• Fractyl Health to Participate in the Upcoming December Conferences | Fractyl Health, Inc.
• Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | Fractyl Health, Inc.
• Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 | Fractyl Health, Inc.
• Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024 | Fractyl Health, Inc.
• News Releases | Fractyl Health, Inc.
• Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024 | Fractyl Health, Inc.
• View more press releases Close

Redes sociais sobre Fractyl Laboratories

• Fractyl Laboratories na Wikipedia, Google News e Yahoo Finance
• Fractyl Laboratories na LinkedIn, X (Twitter) e YouTube